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Abstract
Introduction and hypothesis Prolapse is a common female
problem, and conservative treatments such as pelvic floor
muscle training (PFMT) are important options for women.
Evidence supporting the effectiveness of PFMT for prolapse
has grown over the last decade, and it was hypothesised that
practice and practice guidelines would have developed in line
with the evidence. To assess this, up-to-date information about
the practice of physiotherapists working in women’s health
regarding their treatment of prolapse was required.
Methods An online survey sent to members of the Association
of Chartered Physiotherapists in Women’s Health and the
Chartered Physiotherapists Promoting Continence. Results were
compared with those of an earlier survey undertaken in 2002.
Results A 49 % response rate was achieved. The majority of
respondents were senior physiotherapists (55 %) and had
worked in women’s health for more than 10 years. Respon-
dents were treating significantly more women with prolapse
than a decade before: 36 % vs 14 % treated more than 50
women per year in 2002 and 2013 respectively (p<0.001).
Individualised PFMT (93 %), lifestyle advice (92 %) and
biofeedback-assisted PFMT (83 %) were the most common
treatment elements, with four being the average number of
appointments. Forty-eight percent had changed their practice
as a result of recent research; however, scepticism amongst
medics, the referral of women directly for surgery, and con-
straints on resources were thought to be barriers to wider im-
plementation of the evidence of PFMT for prolapse.
Conclusions There has been uptake of evidence-based pro-
lapse practice by UK specialist physiotherapists in the last
decade. Further research targeting the implementation of this
evidence would be valuable in addressing potential barriers,
and in supporting the need for physiotherapy in the treatment
of prolapse.
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Introduction
Pelvic organ prolapse is a common condition thought to affect
40 % of women over 50 years of age [1]. It is defined as the
descent of one or more of the following: anterior vaginal wall,
posterior vaginal wall, the uterus (cervix), or the apex of the
vagina (vaginal vault or cuff scar after hysterectomy), and
correlates with symptoms [2].
Current treatment for prolapse consists of surgery, conser-
vative management or Bwatchful waiting^. Mechanical inter-
ventions (such as pessaries) and lifestyle interventions (such
as weight loss and avoiding placing strain on the pelvic floor)
are both conservative management options. In addition, many
women’s health physiotherapists offer pelvic floor muscle
training (PFMT). PFMT aims to improve structural support
for pelvic organs through effective exercise of the pelvic floor
muscles [3], and there is robust evidence of its effectiveness as
a treatment for prolapse [4].
Research into the prevention, assessment and effective
treatment of prolapse is crucial, as the prevalence is predicted
to increase substantially as the population ages. Some predict
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that the rate of women seeking treatment for prolapse will
double over the next 30 years [5]. In 2002, a survey was
carried out that reported UK physiotherapy practices in rela-
tion to women with prolapse. The survey sought to establish
the current use of PFMT in the treatment of prolapse and to
provide background information for a planned randomised
controlled trial evaluating the effectiveness of PFMT [6].
Questionnaires were mailed to members of the Association
of Chartered Physiotherapists in Women’s Health (ACPWH,
now renamed “Pelvic, Obstetric and Gynaecological Physio-
therapy”, POGP) to investigate the number of women with
prolapse treated, treatments offered, guidelines and measures
of treatment progress used. The results indicated that PFMT
was widely practiced by women’s health physiotherapists
throughout the UK, with over 96 % of respondents using the
main elements of PFMT during the treatment of prolapse,
despite scarce evidence of effectiveness and a lack of guide-
lines at that time.
Since the publication of this survey, further research has
been conducted assessing the effectiveness of PFMT. The Pel-
vic Organ Prolapse PhysiotherapY (POPPY) multicentre trial
[4] reported a greater reduction in prolapse symptoms after
1 year in women who had received PFMT than in those who
had not. This trial, two other full-size trials [7, 8], and a num-
ber of smaller pilot studies, have begun to establish an evi-
dence base supporting the use of PFMT in the treatment of
prolapse [9].
In 2013, a survey was conducted to explore the hypothesis
that physiotherapy practice with regard to prolapse would
have changed in the last decade in response to the growing
evidence base.
The aims were to:
1. Investigate current physiotherapy practice in the treatment
of prolapse, specifically PFMT, across the UK;
2. Explore the impact of recent research evidence relating to
the conservative management of women with prolapse.
Materials and methods
The original survey tool, developed in 2002, was updated to
gather the necessary data on current physiotherapy practices in
the treatment of prolapse across the UK, including changes
experienced. In line with Cochrane guidance on the use of
electronic surveys [10], the tool was kept short, taking less
than 10 min to complete. The survey was accessed via a link
sent in an email to the potential participants.
Once the survey link was activated, there was introductory
information about the research, followed by a question that
asked for the individual’s consent to take part. Of the remain-
ing 19 questions, 5 explored the grade, additional
qualifications, experience and place of work of the respon-
dents; 7 questions considered current practice in the assess-
ment and treatment of prolapse; and 7 questions investigated
awareness of the POPPY trial and its results. Where appropri-
ate, respondents were able to give free text responses, e.g.
Bother—please specify ,^ Bplease describe^, and Bwhat is the
reason?^
In August 2013, the finalised electronic questionnaire was
sent to a contact in both ACPWH and the Chartered Physio-
therapists Promoting Continence (CPPC), who then distribut-
ed the email to the 519 out of 540 members (96 %) who had
agreed to receive mailings regarding such surveys.
Each questionnaire was completed online anonymously
and participants were asked to respond within 2 weeks of
receiving the email. After 2 weeks, a reminder email was
distributed to all individuals on the initial mailing list as it
was not possible to identify those who had already completed
the online survey from those who had not. A final reminder
email was sent 2 weeks later, before the survey closed on 25
September 2013.
Data were entered and analysed using the Statistical Pack-
age for the Social Sciences (SPSS, version 19). Summary
statistics and Chi-squared tests were used to describe data
and investigate the association between responses. Ethical ap-
proval to undertake the research was granted by Glasgow
Caledonian University Departmental Ethics Committee
(HLS12/116, 06/08/13).
Respondents were physiotherapists registered with the
ACPWH or the CPPC in the UK.
Results
Of the 519 surveys initially sent, 289 responses were received
(56 %). Just over half of responses were received within the
first 2 weeks (51 %, n=147) and the two reminder emails
prompted an additional 142 responses (49 %). Of the 289
responses, 36 were discarded as all questions were submitted
unanswered, which produced a response rate for analysable
data of 253 out of 519 (49 %).
The majority of respondents reported that they were senior
physiotherapists (55 %, n=128), followed by junior (27 %,
n=64) and clinical specialists (18%, n=42). Fifty-five respon-
dents chose not to indicate their grade (19 %). This result is
similar to that of the earlier survey, which reported that the
majority of respondents (59 %, n=211) were senior
physiotherapists.
Fifty-three percent of respondents (n=132) had been work-
ing in women’s health physiotherapy for more than 10 years.
A similar proportion indicated 1–5 years (21 %, n=52) and 6–
10 years (23 %, n=57) of experience. Very few individuals
had worked in women’s health physiotherapy for less than
1 year (3 %, n=8). In the previous survey, there was a broader
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spread of clinical experience amongst respondents, with 33 %
(n=122) working in the field for 5 years or less, 30% (n=108)
had been working between 6 and 10 years and 37 % (n=134)
had more than 10 years’ experience.
Over half of respondents had completed a validated conti-
nence course (51 %, 128 out of 253), whilst Bother^ courses
completed by almost a third (31 %, 79 out of 253) included
advanced bladder and bowel workshops and pelvic floor as-
sessment courses.
Most respondents reported working in the specialty of gy-
naecology or urogynaecology (Table 1). More than half re-
ported that they worked across three or four different special-
ities. BOther^ specialist areas reported included colorectal,
continence, musculoskeletal and sexual health clinics. This
result is similar to that of the previous survey in that the ma-
jority also reported working in gynaecology.
The majority of respondents reported working in an outpa-
tient care setting and over half reported working across two or
more different health settings (Table 1). The Bother^ health
settings reported included community health care and a pri-
vate hospital. In the previous survey a similar result was re-
ported, with the majority working in outpatient care.
Only 3 % of respondents reported they had not assessed or
treated any women with prolapse in the last year, compared
with 9 % reported in the previous survey (Table 1). The ma-
jority had assessed or treated 26 women or more, and this was
significantly more than in the previous survey (Χ2=49.9, df=
3, p<0.001).
There was a significant association (Χ2=13.2, df=6, p=
0.04) between the grade and the number of women assessed
or treated for prolapse (Table 2). This reflects the results of the
2002 survey, where it was reported that physiotherapists at a
higher grade had a higher prolapse caseload.
A large majority of respondents reported that the number of
women referred to them with prolapse had increased in the last
5 years (70%, n=157) with a further 26% (n=59) reporting Bno
change^. Only 4 % (n=10) reported that the number of women
referred to them had decreased over the last 5 years.When asked
what the reasonwas for any change, respondents speculated that
it might be in response to an increased awareness of prolapse
and also an increased awareness among GPs concerning the
benefits of physiotherapy in the treatment of the condition.
Of those respondents who had assessed or treated women
with prolapse, the majority took referrals from gynaecology
and primary health care (Table 3). In the previous survey too,
the majority reported taking referrals from gynaecology; how-
ever, this percentage was even greater. In the current survey,
two thirds of respondents reported receiving referrals from
between three and five different specialities. BOther^ referral
sources included colorectal clinics, health visitors and
midwives.
Respondents offered a range of treatments to women with
prolapse. Themost commonly offered treatments were one-to-
one PFMT and lifestyle advice (Table 3). Biofeedback-
assisted PFMTwas another treatment offered by the majority
in both the previous survey and the current survey. The use of
vaginal cones as a treatment was less commonly reported in
the current survey. Treatments such as the use of a pessary,
pessary + PFMTand group-delivered PFMTwere also report-
ed by respondents to a lesser extent in this survey. These
treatment options were not specifically investigated in the ear-
lier survey. BOther^ treatments offered included Breferral to a
specialist to fit pessary^ and Bbowel and bladder advice^. The
most common number of PFMTappointments usually offered
was four (Table 4).
Almost half of respondents reported that they did not have
access to guidelines outlining what treatments should be of-
fered for prolapse. More than half did not have access to
guidelines stating which women should be offered prolapse
treatment and most did not have access to a prolapse care
pathway. Those who reported having access to guidelines cit-
ed the National Institute for Health and Care Excellence
(NICE), Chartered Society of Physiotherapy (CSP), Royal
College of Obstetricians and Gynaecologists (RCOG) or local
guidelines.
In line with the earlier survey, pelvic floor muscle (PFM)
strength was the most common measure used to monitor pa-
tient progress (Table 5). Methods for grading the severity of
prolapse were used by a smaller group of respondents com-
pared with the 2002 survey. Measures such as the Pelvic Floor
Distress Inventory (PFDI), the Pelvic Floor Impact
Table 1 Specialities, health settings and prolapse workload of





Which speciality do you work within?
Gynaecology 279 (76.6) 197 (77.9)
Obstetrics 273 (75.0) 171 (67.6)
Urology 173 (47.5) 126 (49.8)
Urogynaecology 230 (63.2) 192 (75.9)
Other 53 (14.6) 98 (38.7)
Which of the following health settings do you work in?
Primary care 92 (25.3) 59 (23.3)
Outpatients 318 (87.4) 196 (77.5)
Inpatients 208 (57.1) 92 (36.4)
Private practice 81 (22.3) 84 (33.2)
Other—please describe: 11 (3.0) 20 (7.9)
Number of women with prolapse treated in past year
None 31 (8.5) 8 (3.2)
1–25 164 (45.1) 65 (26.3)
26–50 115 (31.6) 86 (34.8)
51+ 52 (14.3) 88 (35.6)
a Denominator for 2002 survey is n=364
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Questionnaire (PFIQ) and the Electronic Personal Assessment
Questionnaire (EPAQ) were also used by a few respondents.
The International Consultation on Incontinence Questionnaire
(ICIQ) Vaginal Symptoms Score and the Pelvic Organ Pro-
lapse Symptom Score (POP-SS) were the two most common-
ly reported symptom measures used. BOther^ measures used
included the Urogenital Distress Inventory and re-assessing
patient symptoms.
A large majority of respondents were aware of the POPPY
randomised controlled trial (80 %, n=190) and 11 % (n=20)
were involved in the trial. Sixty-eight percent of respondents
(n=128) were aware of the published results, which indicated
that PFMTwas effective for reducing prolapse symptoms, and
almost half (48 %, n=59) reported that these results had made
them change their practice. Specific reasons behind the
change in practice were an increased knowledge of the capa-
bilities of PFMTor increased confidence in suggesting this as
an effective treatment. The majority (56 %, n=67), however,
believed that there were barriers to implementing the delivery
of PFMT for prolapse, including: scepticism amongst medical
practitioners concerning the benefits of physiotherapy; GPs
referring patients for surgery as a first-line treatment before
considering conservative therapy options; and Blimited
resources^.
Discussion
This survey investigated current physiotherapy practice in the
treatment of prolapse and the impact that recent research has
Table 2 Number of women with prolapse assessed or treated in the
previous year, by grade of physiotherapist, 2013 survey
Grade Estimate approximately how many
women have you assessed or treated
for prolapse within the last year
frequency (%)
Total
None 1–25 26–50 51+
Junior 5 (8.1) 19 (30.6) 19 (30.6) 19 (30.6) 62 (100.0)
Senior 2 (1.6) 30 (23.6) 51 (40.2) 44 (34.6) 127 (100.0)
Clinical specialist 1 (2.4) 8 (19.5) 10 (24.4) 22 (53.7) 41 (100.0)
Total 8 (3.5) 57 (24.8) 80 (34.8) 85 (37.0) 230 (100.0)
Table 3 Source of referral of
women for assessment and
treatment, and treatments offered





Where were women with prolapse referred from?
Primary care (GP) 248 (74.5) 189 (74.7)
Community continence service 69 (27.3)
Urology 136 (40.8) 62 (24.5)
Urogynaecology 163 (64.4)
Gynaecology 310 (93.1) 195 (77.1)
Obstetrics 187 (56.3) 116 (45.8)
Self-referred 107 (42.3)
Other 38 (11.4) 32 (12.6)
What treatment might you offer women with prolapse?
PFMT (one-to-one) 322 (96.7) 234 (92.5)
PFMT (classes) 38 (15.0)
Lifestyle advice (e.g. lifting, losing weight) 232 (91.7)
Vaginal cones 117 (35.1) 38 (15.0)





Electrical stimulation 252 (75.7) 169 (66.8)
Pessary 28 (11.1)
Pessary + PFMT 49 (19.4)
Other 52 (15.9) 52 (20.6)
PFMT pelvic floor muscle training, EMG electromyography
aDenominator for 2002 survey is n=333
582 Int Urogynecol J (2016) 27:579–585
had on the physiotherapeutic management of women with the
condition. The responses supported the hypothesis that prac-
tice had adapted in line with the evidence base. An increased
number of women were being referred to physiotherapists for
assessment and treatment of prolapse, from a greater range of
sources, compared with 10 years ago. One-to-one PFMTwas
reported to be the most common conservative treatment for
the condition, with lifestyle advice and biofeedback-assisted
PFMT also very frequently used. The majority of respondents
were aware of evidence from a definitive trial to support the
effectiveness of PFMT in the treatment of prolapse, and al-
most half had used the results to alter their practice.
To our knowledge there are no other surveys with which to
compare our findings. Two other surveys of UK prolapse
practice have been published, but have focused only on sur-
gical treatment [11, 12].
The respondents of this survey did not only report seeing a
greater number of women with prolapse than in the initial
survey, but also an increase in the number over the last 5 years.
When asked to identify reasons for this increase in numbers,
respondents overwhelmingly cited Bincreased awareness^ as
the cause. It was reported that awareness within the general
public about the condition had increased as had practitioners’
awareness of the role of physiotherapy as a treatment. It was
also highlighted that increased evidence and the changing
opinions of practitioners were resulting in a greater number
of referrals to physiotherapists. The respondents also reported
that changing care pathways had led to an increased number of
women being referred to physiotherapy before being consid-
ered for surgery. A few respondents mentioned the negative
impact that the recent media coverage regarding surgery and
mesh implants has had. The responses from the current survey
support those from the 2002 survey in that the physiothera-
pists of a higher grade tended to report assessing or treating a
higher number of patients. This may be because the prolapse
patient might present with co-existing vaginal, urinary, bowel
and sexual symptoms, and thus treatment requires a greater
breadth of knowledge and clinical experience.
Recent research provides evidence of the beneficial effects
of PFMT on prolapse, and almost half of respondents had
changed their practice as a result. The introduction into
Table 4 Average number of PFMT appointments offered by












a Exact figures reported where possible. When a range was given, the
mean was used, and rounded up to a whole number (e.g. for “2–5 ap-
pointments” the mean of 3.5 was rounded to 4)
Table 5 Measures used by
respondents to monitor the
progress of women with prolapse
Do you use any of the following
measures to monitor patient progress?
2002 2013a
Frequency (%) Frequency (%)
Prolapse grading 148 (44.4)
POP-Q 44 (17.8)
Other staging measure (e.g. Baden & Walker) 11 (4.3)
PFM strength (e.g. Oxford scale, ICS method) 313 (94.0) 202 (80.2)
Patient reported symptoms 324 (97.3)





Quality of life 280 (84.1) 5 (2.0)
P-QoL 23 (9.1)
PFIQ 8 (3.2)
Other 23 (6.3) 42 (16.6)
POP-Q Pelvic Organ Prolapse Quantification, PFM pelvic floor muscles, ICIQ International Consultation on
Incontinence Questionnaire, MYMOP Measure Yourself Medical Outcome Profile, POP-SS Pelvic Organ Pro-
lapse Symptom Score, PFDI Pelvic Floor Distress Inventory, EPAQ Electronic Personal Assessment Question-
naire, P-QoL Perceived Quality of Life, PFIQ Pelvic Floor Impact Questionnaire
a Denominator for 2002 survey is n=333
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practice of a wider variety of treatments such as group PFMT
and pessaries was also evident, as was the combination of
PFMTwith a pessary.
Pelvic floor muscle strength was still the most commonly
used measure of treatment progress. It was encouraging that
18 % of respondents were using the POP-Q [13], as the reli-
ability of physiotherapists using the POP-Q has recently been
demonstrated to be good [14], and the availability of such data
is useful for multidisciplinary discussion. A survey of
gynaecologists and urogynaecologists, who may be more
established in their use of the POP-Q, found that 40 % used
the POP-Q in routine clinical practice [15].
There was considerable use of validated symptom mea-
sures, in particular the POP-SS [16] and the ICIQ Vaginal
Symptoms Score [17]. Such symptom outcome measures are
valuable as symptoms are the main driver for women seeking
treatment.
Respondents using guidelines named the National Institute
for Health and Care Excellence (NICE), Royal College of
Obstetricians and Gynaecologists (RCOG) and Chartered So-
ciety of Physiotherapy (CSP) guidelines. NICE propose care
pathways for urinary incontinence in women, advise pelvic
floor exercises in the treatment of stress urinary incontinence,
and offer guidelines on surgical mesh repair in the treatment of
prolapse. However, there are no care pathways, clinical guide-
lines or referral guidelines specific to prolapse. RCOG offer
only guidelines on “post-hysterectomy vaginal vault pro-
lapse”, which state that the role of conservative measures in
treatment, including pelvic floor exercise, is Bunclear .^ The
CSP offers no guidelines of its own, but recommends using
those produced by NICE. Although not mentioned by respon-
dents, the International Consultation on Incontinence text-
book, which synthesises the evidence on incontinence and
other pelvic floor problems, provides a treatment pathway
for prolapse that includes a recommendation for PFMT before
surgical intervention [18]. The need for clear, accessible
guidelines and care pathways is apparent and will become
increasingly important in avoiding large variations in local
practice primarily determined by the practitioners’ individual
experience.
As awareness of the evidence supporting the use of PFMT
continues to grow, it is likely that more practitioners will refer
women for physiotherapy and more physiotherapists will be
required to deliver PFMT. Over half of respondents had spent
more than 10 years working in the field of women’s health.
The future inevitable loss of this vast experience and knowl-
edge of these senior practitioners needs to be planned for.
Pathways into women’s health for physiotherapists in the
UK are limited and need to be considered.
Respondents were working in a wide range of different
specialties and receiving referrals from a range of sources,
highlighting how widespread this problem is. This further
stresses the need for resources and awareness to manage the
expected increase in the prevalence of prolapse within the
population [5].
Although the results of this survey are similar to those
found in the earlier survey carried out by the authors, the
response rate here was lower. This may be accounted for by
the different distribution method used in the recent survey:
email as opposed to postal delivery. Whilst email is a faster
method of communication, an email may have been easier to
overlook or seemed less personal, making respondents less
inclined to respond. Contrary to this, studies comparing email
and postal administration of surveys to healthcare profes-
sionals have indicated that emails are preferred by recipients,
leading to higher response rates [19, 20]. Our response rate of
49 % is, however, similar to the mean response rate of 53 %
found from across 490 published surveys [21].
Despite the lower response rate, the demographics of the
respondents from 2002 and 2013 were similar in that the ma-
jority were senior physiotherapists, and the majority reported
working in gynaecology and saw women in outpatient care.
Thus the profiles of the two samples are similar.
The sampling frame for the survey was the mailing lists of
the ACPWH and CPPC professional organisations. Although
there are women’s health physiotherapists who are not mem-
bers of these professional organisations, and therefore would
not have received this survey directly, we asked respondents
to pass on the survey link to colleagues who were non-mem-
bers. In addition, the survey link was distributed at the
ACPWH annual conference where 18 % of attendees were
non-members.
In conclusion, the survey results indicate that there is
awareness, and has been uptake, of evidence-based practice
in the last decade, and PFMT is being delivered to greater
numbers of women with prolapse by the majority of specialist
physiotherapists. Barriers to further implementation, such as a
lack of trained staff to deliver PFMT and the lack of guide-
lines, need to be addressed to support the growing need for
conservative treatment.
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